Investigational New Drug Applications and New Drug Applications

ICR 200205-0910-003

OMB: 0910-0416

Federal Form Document

Forms and Documents
Document
Name
Status
No forms / supporting documents in this ICR. Check IC Document Collections.
IC Document Collections
ICR Details
0910-0416 200205-0910-003
Historical Active 199908-0910-005
HHS/FDA
Investigational New Drug Applications and New Drug Applications
No material or nonsubstantive change to a currently approved collection   No
Regular
Approved without change 05/28/2002
Retrieve Notice of Action (NOA) 05/28/2002
  Inventory as of this Action Requested Previously Approved
05/31/2002 05/31/2002 10/31/2002
2,028 0 2,028
8,128 0 8,128
0 0 0

For investigational new drug applications (INDs), the rule requires that sponsors submit in their annual reports the numbers of clinical subjects enrolled in their studies by age group, gender, and race. For new drug applications (NDAs), the rule requires that safety and effectiveness data be provided by gender, age, and racial subgroups, among other relevant subgroups.

None
None


No

1
IC Title Form No. Form Name
Investigational New Drug Applications and New Drug Applications

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 2,028 2,028 0 0 0 0
Annual Time Burden (Hours) 8,128 8,128 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$0
No
No
Uncollected
Uncollected
Uncollected
Uncollected

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/28/2002


© 2024 OMB.report | Privacy Policy